This company has been marked as potentially delisted and may not be actively trading. NASDAQ:VSAR Versartis (VSAR) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Versartis Stock (NASDAQ:VSAR) 30 days 90 days 365 days Advanced Chart Get Versartis alerts:Sign Up Key Stats Today's Range$1.18▼$1.3050-Day Range$1.19▼$1.1952-Week Range$1.14▼$2.76Volume349,963 shsAverage Volume479,436 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Aravive, Inc. operates as a clinical stage biotechnology company. The firm engages in the development of new therapies that target important survival pathways for both advanced solid tumors as well as hematologic malignancies. Its product candidate, Aravive-S6, is a soluble Fc-fusion protein designed to block the activation of the GAS6-AXL signaling pathway by intercepting the binding of GAS6 to its receptor AXL which also promotes metastasis, cancer cell survival, resistance to treatments and immune suppression. The company was founded on December 10, 2008 and is headquartered in Houston, TX. Read More Receive VSAR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Versartis and its competitors with MarketBeat's FREE daily newsletter. Email Address VSAR Stock News Headlines16 Biopharma Companies Besides Medivation That Are Attractive TargetsJuly 21, 2023 | thestreet.comDon't Tell Anyone: Insiders Are Buying These Stocks Like CrazyDecember 28, 2022 | thestreet.comThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump could be just weeks away. And it holds the potential to trigger one of the most explosive tech booms in US history. At the center of it all? Robots. Not the kind that clean your house or pour you coffee. But the kind that could reshape entire industries, add $1.2 trillion per year to the US economy, and affect 65 million American lives — just in the next year.August 15 at 2:00 AM | Weiss Ratings (Ad)Zluri Hires Todd Dekkinga as Chief Information Security Officer - Yahoo FinanceOctober 11, 2022 | finance.yahoo.comAscendis Pharma: Biotech Bear Provides Attractive Entry Point - Seeking AlphaMay 9, 2022 | seekingalpha.comVersartis Price Gains on Drug Approval, eHealth Rises: Tech Winners & LosersMarch 21, 2022 | thestreet.comAmphista Therapeutics Appoints New Chairman, Joshua T. Brumm - PRNewswireSeptember 22, 2021 | prnewswire.comCidara Therapeutics Appoints Preetam Shah, Ph.D., MBA, as Chief Financial Officer and Chief Business Officer, and Shane Ward as Chief Legal Officer and Corporate Secretary - Yahoo FinanceSeptember 3, 2021 | finance.yahoo.comSee More Headlines VSAR Stock Analysis - Frequently Asked Questions How were Versartis' earnings last quarter? Versartis, Inc. (NASDAQ:VSAR) issued its quarterly earnings results on Tuesday, August, 7th. The biopharmaceutical company reported ($0.27) earnings per share for the quarter, topping the consensus estimate of ($0.96) by $0.69. What other stocks do shareholders of Versartis own? Based on aggregate information from My MarketBeat watchlists, some other companies that Versartis investors own include Progenics Pharmaceuticals (PGNX), ZIOPHARM Oncology (ZIOP), Bausch Health Cos (BHC), Flexion Therapeutics (FLXN), Genocea Biosciences (GNCA), Novavax (NVAX) and Protalix BioTherapeutics (PLX). Company Calendar Last Earnings8/07/2018Today8/15/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryN/A Current SymbolNASDAQ:VSAR CIK1513818 Webwww.versartis.com Phone(936) 355-1910FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableOptionable BetaN/A Ten Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free Report This page (NASDAQ:VSAR) was last updated on 8/15/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Versartis, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Versartis With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access